The CURE-AF (Clinical Utilization and Evidence Generation for Real-time ECGI in Atrial Fibrillation) project aims to revolutionize the treatment of atrial fibrillation (AF) by validating and scaling Corify Care’s ACORYS system, a non-invasive, real-time electrocardiography imaging (ECGI) technology.

With over 60 million people affected worldwide and treatment failure rates of up to 50%, CURE-AF addresses a critical need: improving the precision and success rate of catheter-based ablation procedures through complete, non-invasive, real-time electrocardiographic mapping of the atria.

As an innovation-to-market project in the field of digital transformation in healthcare (DTH), CURE-AF focuses on clinical validation, market access, and reimbursement strategies in Spain, Portugal, and Germany. As Medical Valley, we are developing the optimal market entry strategy for the German healthcare market.

This research has received funding from the European Institute of Innovation and Technology (EIT) under grant agreement No 250027. This European body receives support from the Horizon 2020 research and innovation programme.

• Analysis of markets, competitors, customer segments, and their needs
• Validation of the business model and value proposition through stakeholder feedback and pilot customers
• Development of a clear, segment-specific value proposition

• Development of a validated, viable, and growth-oriented go-to-market strategy
• Ensuring the marketability of the business model
• Creation of a clear, differentiating value proposition for prioritized customer segments
• Consistent, compelling communication for marketing and sales
• Support for a successful commercial rollout